Xia Li | Diabetes | Best Researcher Award

Published on by Cell Biologist

Prof. Xia Li | Diabetes | Best Researcher Award

Prof. Xia Li, Depart. of Metabolism & Endocrinology, Second Xiangya Hospital, Central South University, China

Dr. Xia Li is a prominent physician-scientist and academic leader in the field of endocrinology and metabolism. She serves as Professor and Director of the Department of Metabolism & Endocrinology at the Second Xiangya Hospital, Central South University. Additionally, she holds the position of Vice-director at the National Clinical Research Center for Metabolic Diseases and Vice-chairman of the China Type 1 Diabetes Alliance. Dr. Li is a prolific contributor to global diabetes research, particularly in Type 1 Diabetes (T1D), with over 100 publications in leading journals including Nature Communications, Diabetologia, and Diabetes Care. As an editor for the Journal of Clinical Endocrinology & Metabolism and Journal of the Endocrine Society, she contributes significantly to scholarly discourse. Her pioneering work includes establishing a T1D cohort in China, exploring immunological aging, and driving improvements in personalized diabetes management.

Publication Profile: 

Scopus

✅ Strengths for the Award:

  1. Leadership in Clinical and Research Roles

    • Director of Metabolism & Endocrinology at the prestigious Second Xiangya Hospital.

    • Vice-director of a national-level research center for metabolic diseases.

    • Vice-chairman of the China Type 1 Diabetes Alliance.

  2. High-Impact Research and Publications

    • Over 100 peer-reviewed publications in top journals like Nature Communications, Diabetologia, Diabetes Care, and Sleep Medicine.

    • Research addresses critical issues in Type 1 Diabetes (T1D), including disease progression, glycemic variability, AI applications, and long-term complications.

  3. Innovative Contributions

    • Established a national T1D follow-up cohort focused on clinical, immunological, and genetic characteristics—critical for personalized medicine.

    • Pioneered research on immunological aging in GDM offspring, indicating intergenerational effects of diabetes.

  4. Academic Service & Influence

    • Serves on the editorial boards of the Journal of Clinical Endocrinology & Metabolism and Journal of The Endocrine Society.

    • Involved in large-scale international efforts (e.g., T1D Index, IDF Atlas 2025).

  5. Interdisciplinary Expertise

    • Combines endocrinology, immunology, AI (e.g., neural Turing machines), and epidemiology to tackle diabetes holistically.

🔧 Areas for Improvement:

  1. International Recognition Expansion

    • While highly respected in China, global visibility (especially in Western institutions and conferences) could be enhanced further.

    • Publishing in more open-access and globally visible platforms may improve reach.

  2. Cross-disciplinary Collaborations

    • Further collaboration with AI labs and data science teams outside the medical field can help accelerate predictive modeling in diabetes.

  3. Translation to Policy and Practice

    • Although the research is strong, structured efforts to influence national diabetes policy or produce public health guidelines would elevate her societal impact.

🎓 Education:

Professor Xia Li earned her MD and completed her medical training in internal medicine and endocrinology from Central South University, one of China’s leading medical institutions. She later pursued advanced academic and clinical training in metabolic diseases and immunology, contributing to the global understanding of diabetes pathogenesis. With a strong foundation in clinical sciences, she combined this with extensive research exposure to endocrinology, particularly Type 1 Diabetes (T1D), autoimmune mechanisms, and metabolic complications. Her education provided her with a multidisciplinary approach, integrating genomics, immunology, and endocrinology to innovate treatment strategies and diagnostic models. Through her education, Dr. Li laid the groundwork for a career that bridges cutting-edge research and transformative clinical practice.

💼 Experience:

Dr. Xia Li has over two decades of experience in clinical endocrinology, metabolic disease research, and academic leadership. As the Director of the Department of Metabolism & Endocrinology at Second Xiangya Hospital and Vice-director of the National Clinical Research Center for Metabolic Diseases, she leads critical national-level initiatives. She also plays a key leadership role as Vice-chairman of the China Type 1 Diabetes Alliance. In research, she has been instrumental in establishing a longitudinal T1D cohort to study disease progression and remission phases. As an editorial board member for leading endocrine journals, she supports high-impact scientific publishing. Her expertise spans clinical trials, biomarker discovery, AI in metabolic diseases, and population health. With a vast international network and interdisciplinary collaborations, Dr. Li has also mentored numerous students and clinicians, reinforcing her influence in both clinical and academic endocrinology.

🔬 Research Focus:

Professor Xia Li’s research focuses primarily on Type 1 Diabetes (T1D), including its immunological, genetic, and clinical characteristics. She established a nationwide T1D follow-up cohort to explore disease remission and progression stages, offering new insights into pathophysiology. Her studies examine monocyte aging, autoimmunity, sleep’s role in glucose regulation, and the efficacy of AI and automated insulin delivery systems. She is also engaged in research on gestational diabetes’ intergenerational effects, insulin resistance, and executive dysfunction in diabetic populations. Furthermore, Dr. Li explores AI-driven prognostics and the impact of cumulative glycemic exposure. Her work aims to personalize diabetes treatment, improve early diagnosis, and prevent complications. Her integrative approach includes systems biology, time-series analysis, and national public health frameworks, positioning her as a leading investigator bridging laboratory research with real-world clinical practice.

📚 Publications Top Notes: 

  1. 🧬 Immunological age prediction of monocytes in GDM offspring – Immunity and Ageing, 2025

  2. 🛌 The effect of sleep quality on glucose variability in T1D adolescents in China – Sleep Medicine, 2025

  3. 🌍 Global T1D prevalence, incidence & mortality estimates – IDF Atlas 2025 – Diabetes Research and Clinical Practice, 2025

  4. 🧠 Executive function deficits in adults with childhood-onset T1D – Journal of Diabetes Investigation, 2025

  5. 🤖 Efficacy and safety of automated insulin delivery systems: A meta-analysis – Diabetes Metabolism Journal, 2025

  6. 🩸 HbA1c and insulin dose roles in insulin resistance-related disorders – Chinese Journal of Internal Medicine, 2025

  7. 🏥 Practice insights of the National Diabetes Prevention Center (DPCC) in Hunan – Journal of Chinese Physician, 2025

  8. 🧪 Differential diagnosis among T1DM, T2DM, and monogenic diabetes – Chinese Journal of Diabetes Mellitus, 2025

  9. 👩‍⚕️ Tribute to Prof. Wu Hanwen, pioneer of metabolism in China – Chinese Journal of Diabetes Mellitus, 2025

  10. 🧠🧮 Interpretable neural Turing machine for T2DM prognosis – International Journal of Medical Informatics, 2025

🏁 Conclusion:

Professor Xia Li is an exceptionally qualified candidate for the Best Researcher Award. Her groundbreaking work in Type 1 Diabetes, leadership roles in both clinical and research institutions, and her commitment to advancing personalized medicine through multi-center studies and AI-driven analytics, position her as a transformative figure in global endocrinology.

Naoki Harada | Molecular Mechanisms Signaling | Best Researcher Award

Published on by Cell Biologist

Dr. Naoki Harada | Molecular Mechanisms Signaling | Best Researcher Award

Dr. Naoki Harada, Osaka Metropolitan University, Japan

Naoki Harada is an Associate Professor at Osaka Metropolitan University, Japan, with extensive expertise in molecular biology, biochemistry, endocrinology, and nutrition. He earned his Ph.D. in Life Sciences from Osaka Prefecture University in 2007. Over the past two decades, Harada has made significant contributions to understanding the physiological and biochemical mechanisms underpinning metabolic diseases, particularly type 2 diabetes. His research, characterized by high citation impact (H-index of 25), centers on pancreatic β-cell function and metabolic regulation. He has published 77 peer-reviewed articles and holds a patent related to therapeutic interventions. Harada has collaborated with leading scientists like Professors Hiroshi Inui and Ryoichi Yamaji, strengthening his academic footprint in both national and international circles. A member of multiple scientific societies, Harada continues to influence the field through impactful research, industry collaboration, and educational leadership.

Publication Profile: 

Orcid

✅ Strengths for the Award:

  1. Consistent Research Output

    • 77 peer-reviewed publications in reputable journals (SCI, Scopus).

    • Recent high-impact studies published in Journal of Biological Chemistry, Scientific Reports, and FASEB BioAdvances.

    • Active research profile with an H-index of 25 and over 1,785 citations.

  2. Innovative Scientific Contributions

    • Identified REDD2 as a novel therapeutic target for type 2 diabetes—bridging basic research with translational medicine.

    • Works across disciplines such as molecular biology, endocrinology, and nutritional biochemistry.

  3. Project Leadership & Industry Engagement

    • Led or participated in 14 major research projects.

    • 5 consultancy/industry-based projects, reflecting application-oriented research.

  4. Academic and Collaborative Network

    • Strong academic collaborations with Professors Hiroshi Inui and Ryoichi Yamaji.

    • Member of prestigious scientific societies (e.g., Japanese Biochemical Society, Japan Society of Nutrition and Food Science).

  5. Scientific Versatility

    • Contributions span fundamental mechanisms (e.g., oxidative stress, insulin signaling) to dietary interventions (e.g., mogrol, oleamide).

    • Demonstrates ability to bridge molecular insights with systemic physiological outcomes.

⚙️ Areas for Improvement:

  1. International Visibility and Engagement

    • Expanding participation in international conferences and editorial boards could elevate his global scientific standing.

    • Pursuing cross-border collaborations would further enrich the translational value of his work.

  2. Commercialization and Patent Activity

    • While one patent is noted, increased focus on intellectual property development and biomedical commercialization could further validate his applied research strength.

  3. Outreach and Communication

    • More active public science communication (e.g., webinars, policy advocacy, media coverage) would amplify the societal impact of his research.

🎓 Education:

Naoki Harada received his Ph.D. in Life Sciences from Osaka Prefecture University, Osaka, Japan, in September 2007. His doctoral studies laid the foundation for his interdisciplinary research in molecular biology, biochemistry, and endocrinology. Harada’s academic path was driven by a keen interest in the cellular and molecular mechanisms underlying metabolic regulation, particularly in relation to glucose homeostasis and pancreatic function. His education provided him with a solid grounding in experimental techniques, critical thinking, and scientific communication, which have become hallmarks of his later work. The institution, known for excellence in biosciences, enabled Harada to cultivate a strong research acumen. His academic training was complemented by exposure to applied research, linking basic science with clinical and nutritional applications—an approach that he has continued to emphasize throughout his career. His strong educational background plays a pivotal role in his current research endeavors and professional development.

💼 Experience:

Dr. Naoki Harada began his academic career in 2008 as an Assistant Professor at the Graduate School of Life and Environmental Sciences, Osaka Prefecture University. He was promoted to Lecturer in 2015, and subsequently to Associate Professor in 2019. Since 2022, he has served as Associate Professor at the Graduate School of Agriculture, Osaka Metropolitan University. Harada has consistently combined teaching with intensive research, mentoring graduate students while advancing his lab’s focus on metabolic diseases and endocrine physiology. His experience includes leading 14 research projects, consulting on 5 industry-linked nutrition initiatives, and co-authoring over 75 scientific papers. His experience reflects a blend of academic leadership, scientific innovation, and multidisciplinary collaboration. Notably, Harada’s role in identifying REDD2 as a therapeutic target exemplifies his contribution to translational science. He maintains strong academic partnerships and actively contributes to several professional societies, making him a respected figure in Japan’s scientific community.

🔬 Research Focus:

Naoki Harada’s research is at the intersection of molecular biology, endocrinology, and nutrition science, with a particular focus on pancreatic β-cell physiology and glucose metabolism. He investigates how oxidative stress, hormonal signals, and metabolic regulators influence insulin secretion and β-cell viability. One of his pivotal contributions is identifying the REDD2 gene as a negative regulator of β-cell function, offering novel therapeutic targets for type 2 diabetes mellitus. His studies also explore nutrient-sensing pathways, G-protein-coupled receptors, and hormonal modulation of energy metabolism. Harada’s recent work delves into the effects of dietary compounds like mogrol and oleamide on metabolic health, linking molecular mechanisms to real-world dietary interventions. His ability to bridge bench science with clinical and nutritional applications sets his research apart. Through collaborations with leading experts and high-impact publications, Harada continues to advance knowledge in the prevention and treatment of metabolic disorders.

📚 Publications Top Notes:

  • 🧬 REDD2 confers pancreatic β-cell dysfunction in high-fat diet-fed mice – Journal of Biological Chemistry, 2025

  • 🦷 Androgens suppress ST3GAL1/4, modulating mucin glycosylation and microbiota in mice – Bioscience, Biotechnology, and Biochemistry, 2025

  • 🍟 CRTC1 in MC4R cells regulates dietary fat intake – FASEB BioAdvances, 2024

  • 💉 Insulin reduces ER stress-induced apoptosis in INS-1 β-cells – Physiological Reports, 2024

  • 🍬 Mogrol activates GPBAR1 and insulin secretion, alleviates hyperglycemia – Scientific Reports, 2024

  • 🔥 Androgen receptor suppresses β-adrenoceptor-mediated thermogenesis – Journal of Biological Chemistry, 2022

  • 🏥 Age-dependent sex differences in NAFLD in TSOD and db/db mice – PLOS ONE, 2022

  • 🐭 Dietary oleamide attenuates obesity in caged mice – Bioscience, Biotechnology, and Biochemistry, 2022

  • 🌿 Curcumin targets GPR55 receptor – npj Science of Food, 2022

  • 💪 Oleamide rescues muscle atrophy in small-caged mice – British Journal of Nutrition, 2021

🧾 Conclusion:

Dr. Naoki Harada demonstrates a clear trajectory of research excellence, grounded in scientific rigor and driven by impactful biomedical questions. His ability to identify molecular mechanisms (e.g., REDD2’s role in β-cell dysfunction) and propose therapeutic directions sets him apart as a leading academic in metabolic disease research. His publication record, industry collaborations, and professional memberships underscore a mature and influential academic career.